PMID- 30446366
OWN - NLM
STAT- MEDLINE
DCOM- 20190401
LR  - 20190401
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 61
DP  - 2019 Mar
TI  - Efficacy, tolerability, and blood concentration of zonisamide in daily clinical 
      practice.
PG  - 44-47
LID - S0967-5868(18)30339-4 [pii]
LID - 10.1016/j.jocn.2018.11.012 [doi]
AB  - We aimed to evaluate the efficacy, tolerability, and blood concentration of 
      zonisamide (ZNS) used in daily clinical practice. This was a retrospective study 
      performed at a single epilepsy center and included 149 patients with epilepsy. 
      The efficacy and retention of ZNS for 52 weeks, percentage of patients who were 
      seizure free for 26 weeks, and the 5-year retention rate were analyzed. The 
      tolerability was assessed based on treatment-emergent adverse effects (AEs) and 
      the adverse effect profile (AEP). More than 70% (105/149) of patients were on ZNS 
      polytherapy. The mean dose of ZNS was 300 +/- 170.6 mg/day, and the antiepileptic 
      drug (AED) load was 2.0 +/- 1.1 (median 1.8, range 0.2-5.3). The retention rate for 
      52 weeks and the percentage of patients who were seizure-free for 26 weeks were 
      73% and 42%, respectively. The retention rate decreased with time and reached 43% 
      in 5 years. Younger age of onset was a significant variable affecting retention 
      rate for 52 weeks (p = 0.044), whereas fewer concomitant AEDs were significantly 
      associated with being seizure free for 26 weeks (p = 0.0006). AEs were reported 
      in 24% (36/147) of patients. The number, mechanism of action, or drug load of the 
      AEDs did not predict the development of AEs; however, blood concentration of ZNS 
      was significantly higher in patients with AEs (p = 0.0011) than in those without 
      AEs. ZNS is a well-tolerated and effective AED in daily clinical practice, and 
      several clinical factors may predict the efficacy and tolerability of ZNS.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Park, Kang Min
AU  - Park KM
AD  - Department of Neurology, Haeundae Paik Hospital, Inje University College of 
      Medicine, Busan, Republic of Korea.
FAU - Lee, Byung In
AU  - Lee BI
AD  - Department of Neurology, Haeundae Paik Hospital, Inje University College of 
      Medicine, Busan, Republic of Korea.
FAU - Shin, Kyong Jin
AU  - Shin KJ
AD  - Department of Neurology, Haeundae Paik Hospital, Inje University College of 
      Medicine, Busan, Republic of Korea.
FAU - Ha, Sam Yeol
AU  - Ha SY
AD  - Department of Neurology, Haeundae Paik Hospital, Inje University College of 
      Medicine, Busan, Republic of Korea.
FAU - Park, JinSe
AU  - Park J
AD  - Department of Neurology, Haeundae Paik Hospital, Inje University College of 
      Medicine, Busan, Republic of Korea.
FAU - Kim, Si Eun
AU  - Kim SE
AD  - Department of Neurology, Haeundae Paik Hospital, Inje University College of 
      Medicine, Busan, Republic of Korea.
FAU - Kim, Sung Eun
AU  - Kim SE
AD  - Department of Neurology, Haeundae Paik Hospital, Inje University College of 
      Medicine, Busan, Republic of Korea. Electronic address: epidoc@inje.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20181113
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Anticonvulsants)
RN  - 459384H98V (Zonisamide)
SB  - IM
CIN - J Clin Neurosci. 2019 May;63:283. PMID: 30773475
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anticonvulsants/*therapeutic use
MH  - Epilepsy/*drug therapy
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Seizures/prevention & control
MH  - Treatment Outcome
MH  - Young Adult
MH  - Zonisamide/*therapeutic use
OTO - NOTNLM
OT  - Anticonvulsants
OT  - Epilepsy
OT  - Zonisamide
EDAT- 2018/11/18 06:00
MHDA- 2019/04/02 06:00
CRDT- 2018/11/18 06:00
PHST- 2018/02/26 00:00 [received]
PHST- 2018/10/29 00:00 [revised]
PHST- 2018/11/05 00:00 [accepted]
PHST- 2018/11/18 06:00 [pubmed]
PHST- 2019/04/02 06:00 [medline]
PHST- 2018/11/18 06:00 [entrez]
AID - S0967-5868(18)30339-4 [pii]
AID - 10.1016/j.jocn.2018.11.012 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2019 Mar;61:44-47. doi: 10.1016/j.jocn.2018.11.012. Epub 2018 
      Nov 13.